利拉鲁肽+阿法骨化醇治疗老年2型糖尿病合并骨质疏松患者的临床效果

Clinical effect of liraglutide + alfacalcidol in the treatment of elderly patients with type 2 diabetes mellitus combined with osteoporosis

目的探究利拉鲁肽+阿法骨化醇治疗老年2型糖尿病合并骨质疏松患者的临床效果。方法选取本院2018年1月至2020年1月收治的96例老年2型糖尿病合并骨质疏松患者为研究对象,遵循数字随机法将其分为参照组(n=48)和研究组(n=48)。参照组采用阿法骨化醇进行治疗,研究组采用利拉鲁肽+阿法骨化醇进行治疗。比较两组患者治疗前、后的血糖指标、骨代谢指标及BMD、骨质疏松症症状评分及不良反应发生情况。结果治疗后,研究组患者的空腹血糖、餐后2 h血糖水平及糖化血红蛋白均低于参照组,差异有统计学意义(P<0.05)。治疗后,研究组患者的β-CTX水平低于参照组,骨钙素水平及BMD高于参照组,差异有统计学意义(P<0.05)。治疗后,两组患者的腰背疼痛、腰膝酸软、目眩、步履艰难、下肢痿弱、下肢疼痛评分均降低,且研究组低于参照组,差异有统计学意义(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论利拉鲁肽+阿法骨化醇治疗老年2型糖尿病合并骨质疏松患者,有助于改善患者的血糖水平、BMD、骨代谢指标水平和临床症状。

Objective To investigate the clinical effect of liraglutide+alfacalcidol in the treatment of elderly patients with type 2 diabetes mellitus combined with osteoporosis.Methods Ninety-six elderly patients with type 2 diabetes mellitus combined with osteoporosis admitted in our hospital from January 2018 to January 2020 were selected as the study objects.The patients were divided into reference group(n=48)and study group(n=48)according to digital random method.The reference group was treated with alfacalcidol,and the study group was treated with liraglutide+alfacalcidol.Blood glucose indexes,bone metabolism indexes and BMD,osteoporosis symptom score before and after treatment and the occurrence of adverse reactions were compared between the two groups.Results After treatment,fasting blood glucose,2 h postprandial blood glucose levels and glycosylated hemoglobin in the study group were lower than those in the reference group,and the differences were statistically significant(P<0.05).After treatment,β-CTX level in the study group was lower than that in the reference group,osteocalcin level and BMD were higher than those in the reference group,and the differences were statistically significant(P<0.05).After treatment,the scores of low back pain,weak waist and knees,dizziness,walking difficulty,lower extremity weakness and lower extremity pain in the two groups deareased,and those in the study group were lower than the reference group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Liraglutide+alfacalcidol in the treatment of elderly patients with type 2 diabetes mellitus combined with osteoporosis can help to improve the blood glucose level,BMD,bone metabolism indexes and clinical symptoms.